Literature DB >> 7742809

Administration-route dependency of absorption of glycyrrhizin in rats: intraperitoneal administration dramatically enhanced bioavailability.

Y Yamamura1, T Santa, H Kotaki, K Uchino, Y Sawada, T Iga.   

Abstract

The pharmacokinetic behavior of glycyrrhizin after intravenous (i.v.), oral and intraperitoneal (i.p.) administration was compared in rats. The elimination half-life, total body clearance and volume of distribution at steady-state of glycyrrhizin were not significantly different among doses (2, 10 and 50 mg/kg i.v.). Glycyrrhizin was only detected in the plasma (maximum level: 1.3 micrograms/ml) after oral administration of 50 mg/kg. From comparison of the area under the plasma concentration-time curves after i.v. and oral administration of 50 mg/kg, the bioavailability of glycyrrhizin was estimated to be approximately 1%. Glycyrrhizin was stable for at least 3 h in gastric juice. The plasma concentration of glycyrrhizin after oral administration to neomycin-treated rats was not significantly different from that after administration to untreated rats. Furthermore, in in situ absorption study the cumulative ratio of glycyrrhizin in the mesenteric venous plasma after injection was only 1-2% of the dose. From these results, it appeared that the extremely low bioavailability by the oral route may be due to poor absorption of glycyrrhizin from the intestinal tract. On the other hand, the plasma concentration of glycyrrhizin rapidly increased after i.p. administration of doses of 2, 10 and 50 mg/kg, and reached a maximum level (4.7, 33.0 and 238.9 micrograms/ml, respectively) within 30 min. The bioavailability (65-90%) of glycyrrhizin after i.p. administration was enhanced dramatically. The i.p. route of administration may thus improve the bioavailability of glycyrrhizin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7742809     DOI: 10.1248/bpb.18.337

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  10 in total

1.  Glycyrrhizin Alleviates Nonalcoholic Steatohepatitis via Modulating Bile Acids and Meta-Inflammation.

Authors:  Tingting Yan; Hong Wang; Lijuan Cao; Qiong Wang; Shogo Takahashi; Tomoki Yagai; Guolin Li; Kristopher W Krausz; Guangji Wang; Frank J Gonzalez; Haiping Hao
Journal:  Drug Metab Dispos       Date:  2018-06-29       Impact factor: 3.922

2.  Effects of glycyrrhizin on lipopolysaccharide-induced acute lung injury in a mouse model.

Authors:  Song Am Lee; Seung Hyun Lee; Jin Yong Kim; Woo Surng Lee
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

3.  Natural Nano-Drug Delivery System in Coptidis Rhizoma Extract with Modified Berberine Hydrochloride Pharmacokinetics.

Authors:  Jing Zhao; Qing Zhao; Jing-Ze Lu; Dan Ye; Sheng Mu; Xiao-Di Yang; Wei-Dong Zhang; Bing-Liang Ma
Journal:  Int J Nanomedicine       Date:  2021-09-14

4.  Glycyrrhizin ameliorates metabolic syndrome-induced liver damage in experimental rat model.

Authors:  Rajarshi Sil; Doel Ray; Abhay Sankar Chakraborti
Journal:  Mol Cell Biochem       Date:  2015-09-23       Impact factor: 3.396

5.  The persistent release of HMGB1 contributes to tactile hyperalgesia in a rodent model of neuropathic pain.

Authors:  Polina Feldman; Michael R Due; Matthew S Ripsch; Rajesh Khanna; Fletcher A White
Journal:  J Neuroinflammation       Date:  2012-07-23       Impact factor: 8.322

6.  Glycyrrhetic acid synergistically enhances β₂-adrenergic receptor-Gs signaling by changing the location of Gαs in lipid rafts.

Authors:  Qian Shi; Yuanyuan Hou; Jie Hou; Penwei Pan; Ze Liu; Min Jiang; Jie Gao; Gang Bai
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

7.  Diammonium glycyrrhizinate upregulates PGC-1α and protects against Aβ1-42-induced neurotoxicity.

Authors:  Xiaolei Zhu; Cong Chen; Dan Ye; Dening Guan; Lan Ye; Jiali Jin; Hui Zhao; Yanting Chen; Zhongyuan Wang; Xin Wang; Yun Xu
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

8.  Antibiotic Therapy Using Phage Depolymerases: Robustness Across a Range of Conditions.

Authors:  Han Lin; Matthew L Paff; Ian J Molineux; James J Bull
Journal:  Viruses       Date:  2018-11-12       Impact factor: 5.048

9.  Magnesium isoglycyrrhizinate inhibits airway inflammation in rats with chronic obstructive pulmonary disease.

Authors:  Ye Yang; Lei Huang; Chongchong Tian; Bingjun Qian
Journal:  BMC Pulm Med       Date:  2021-11-15       Impact factor: 3.317

10.  Glycyrrhizin regulates rat TMJOA progression by inhibiting the HMGB1-RAGE/TLR4-NF-κB/AKT pathway.

Authors:  Zhihui Hu; Mian Xiao; Hengxing Cai; Wei Li; Wei Fang; Xing Long
Journal:  J Cell Mol Med       Date:  2021-12-24       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.